Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.79 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.77 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.74 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.57 |
| ▸ | TSHR | P16473 | 1/20 | 0.57 |
| ▸ | DRD2 | P14416 | 1/20 | 0.56 |
| ▸ | HTR2B | P41595 | 1/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30118894 | 1.00 | SIGMAR1 (0.79) | SIGMAR1KCNH2HRH3CYP2D6TSHR | |
| SCHEMBL30118922 | 0.91 | SIGMAR1 (0.65) | SIGMAR1KCNH2HRH3CYP2D6TSHR | |
| SCHEMBL23926367 | 0.91 | SIGMAR1 (0.65) | SIGMAR1KCNH2HRH3CYP2D6TSHR | |
| SCHEMBL14514792 | 0.84 | CYP2A13 (0.63) | SIGMAR1CYP2D6TSHRDRD2HTR2B | |
| SCHEMBL10782490 | 0.83 | CYP2A13 (0.61) | SIGMAR1CYP2D6TSHRDRD2HTR2B | |
| SCHEMBL8672312 | 0.81 | SIGMAR1 (0.79) | SIGMAR1KCNH2HRH3CYP2D6DRD2 | |
| SCHEMBL9086865 | 0.81 | SIGMAR1 (0.51) | SIGMAR1KCNH2HRH3 | |
| SCHEMBL17828187 | 0.80 | SIGMAR1 (0.77) | SIGMAR1KCNH2HRH3 | |
| SCHEMBL12818306 | 0.80 | SIGMAR1 (0.77) | SIGMAR1KCNH2HRH3DRD2HTR2B | |
| SCHEMBL15143993 | 0.80 | SMN1; SMN2 (0.54) | SIGMAR1KCNH2HRH3CYP2D6TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4168408-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2023-04-26 | — | — | EP | disclosed |
| CN-115667256-A | Compounds for treating diseases and methods of treating diseases | 艾特里提治疗有限公司 | 2023-01-31 | — | — | CN | disclosed |
| WO-2021253091-A1 | COMPOUNDS FOR AND METHODS OF TREATING DISEASES | Alterity Therapeutics Limited (AU) | 2021-12-23 | — | — | WO | disclosed |
| US-11155547-B1 | Compounds for and methods of treating diseases | Alterity Therapeutics Limited (AU) | 2021-10-26 | — | — | US | disclosed |
| CN-108137518-A | As 6 inhibitor of histone deacetylase 1,3,4- oxadiazole derivatives compound and include its pharmaceutical composition | 株式会社钟根堂 | 2018-06-08 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11155547-B1 | Compounds for and methods of treating diseases | HTT, SNCA, PARK7 | SIGMAR1 3913/4885KCNH2 3907/4885HRH3 558/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.